MYH10

Summary

MYH10 (myosin heavy chain 10, HGNC:7568) is a protein-coding gene on chromosome 17p13.1, encoding Myosin-10 (P35580). Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.

This gene encodes a member of the myosin superfamily. The protein represents a conventional non-muscle myosin; it should not be confused with the unconventional myosin-10 (MYO10). Myosins are actin-dependent motor proteins with diverse functions including regulation of cytokinesis, cell motility, and cell polarity. Mutations in this gene have been associated with May-Hegglin anomaly and developmental defects in brain and heart. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 4628 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder with or without congenital anomalies (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 1
• Clinical variants (ClinVar): 334 total — 4 pathogenic, 7 likely-pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001256012

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7568
Approved symbol	MYH10
Name	myosin heavy chain 10
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	NMMHCB
Ensembl gene	ENSG00000133026
Ensembl biotype	protein_coding
OMIM	160776
Entrez	4628

Gene structure

Transcript identifiers

Ensembl transcripts: 57 — 34 protein_coding, 19 retained_intron, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000269243, ENST00000360416, ENST00000379980, ENST00000411957, ENST00000459986, ENST00000465458, ENST00000469865, ENST00000472728, ENST00000476737, ENST00000488329, ENST00000584124, ENST00000684843, ENST00000685418, ENST00000685631, ENST00000685736, ENST00000685884, ENST00000686521, ENST00000686654, ENST00000686956, ENST00000687178, ENST00000687661, ENST00000688497, ENST00000688902, ENST00000689318, ENST00000690548, ENST00000690895, ENST00000691566, ENST00000692077, ENST00000692526, ENST00000692894, ENST00000693441, ENST00000693704, ENST00000916044, ENST00000916045, ENST00000916046, ENST00000916047, ENST00000916048, ENST00000916049, ENST00000916050, ENST00000916051, ENST00000916052, ENST00000916053, ENST00000916054, ENST00000916055, ENST00000916056, ENST00000916057, ENST00000916058, ENST00000916059, ENST00000916060, ENST00000916061, ENST00000916062, ENST00000916063, ENST00000916064, ENST00000916065, ENST00000955183, ENST00000955184, ENST00000955185

RefSeq mRNA: 4 — MANE Select: NM_001256012 NM_001256012, NM_001256095, NM_001375266, NM_005964

CCDS: CCDS11144, CCDS58515, CCDS73984, CCDS92256

Canonical transcript exons

ENST00000360416 — 43 exons

Exon	Start	End
ENSE00000000034	8630654	8630725
ENSE00000948819	8542107	8542280
ENSE00000948828	8513786	8513894
ENSE00000948831	8513538	8513669
ENSE00000948832	8512451	8512657
ENSE00000948833	8509812	8509949
ENSE00000948835	8506318	8506489
ENSE00000948836	8504694	8504906
ENSE00000948837	8500826	8500970
ENSE00000948838	8499270	8499476
ENSE00001061754	8535758	8535931
ENSE00001104401	8492297	8492509
ENSE00001104414	8476876	8477048
ENSE00001104417	8495137	8495241
ENSE00001104424	8478338	8478446
ENSE00001104433	8493733	8493885
ENSE00001104437	8492776	8493024
ENSE00001104460	8490340	8490552
ENSE00001104470	8481322	8481410
ENSE00001104483	8518631	8518791
ENSE00001104491	8521092	8521285
ENSE00001104499	8487433	8487594
ENSE00001104513	8484138	8484266
ENSE00001126513	8545448	8545600
ENSE00001126517	8546544	8546662
ENSE00001404859	8576643	8576672
ENSE00001483259	8474224	8475948
ENSE00001524390	8530623	8530685
ENSE00001691289	8518881	8518950
ENSE00001713158	8604826	8604982
ENSE00001734045	8520878	8520999
ENSE00001736135	8535387	8535501
ENSE00001741403	8553955	8554018
ENSE00003460270	8508554	8508677
ENSE00003479454	8548644	8548787
ENSE00003504647	8552046	8552144
ENSE00003544052	8589081	8589108
ENSE00003561960	8577236	8577338
ENSE00003577774	8548313	8548408
ENSE00003580582	8480110	8480318
ENSE00003617403	8569720	8569812
ENSE00003650374	8480402	8480525
ENSE00003923705	8622902	8623277

Expression profiles

Bgee: expression breadth ubiquitous, 300 present calls, max score 99.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.5697 / max 997.9248, expressed in 1552 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164439	27.2661	1503
164441	5.3053	1395
164442	1.5403	776
164443	0.7515	434
164440	0.5475	333
164444	0.1591	56

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood vessel layer	UBERON:0004797	99.92	gold quality
saphenous vein	UBERON:0007318	99.44	gold quality
right coronary artery	UBERON:0001625	99.36	gold quality
ascending aorta	UBERON:0001496	99.31	gold quality
thoracic aorta	UBERON:0001515	99.30	gold quality
descending thoracic aorta	UBERON:0002345	99.08	gold quality
middle temporal gyrus	UBERON:0002771	99.04	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.81	gold quality
vena cava	UBERON:0004087	98.80	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.76	gold quality
visceral pleura	UBERON:0002401	98.74	gold quality
pleura	UBERON:0000977	98.47	gold quality
endothelial cell	CL:0000115	98.45	gold quality
parietal pleura	UBERON:0002400	98.42	gold quality
aorta	UBERON:0000947	98.39	gold quality
lower lobe of lung	UBERON:0008949	98.09	gold quality
postcentral gyrus	UBERON:0002581	98.05	gold quality
orbitofrontal cortex	UBERON:0004167	97.99	gold quality
entorhinal cortex	UBERON:0002728	97.91	gold quality
parietal lobe	UBERON:0001872	97.90	gold quality
placenta	UBERON:0001987	97.89	gold quality
coronary artery	UBERON:0001621	97.85	gold quality
superficial temporal artery	UBERON:0001614	97.77	gold quality
germinal epithelium of ovary	UBERON:0001304	97.75	gold quality
artery	UBERON:0001637	97.73	gold quality
popliteal artery	UBERON:0002250	97.72	gold quality
tibial artery	UBERON:0007610	97.71	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.70	gold quality
renal medulla	UBERON:0000362	97.69	gold quality
superior frontal gyrus	UBERON:0002661	97.65	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	4510.98
E-HCAD-36	yes	2422.09
E-MTAB-8530	yes	367.90
E-HCAD-10	yes	62.61
E-CURD-112	yes	43.33
E-HCAD-6	yes	42.18
E-CURD-46	yes	9.64
E-GEOD-124472	no	913.35
E-CURD-97	no	205.97
E-MTAB-9689	no	201.57
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1, EGR1, GLI3, HHEX, HOXB7, KLF4, KLF5, KLF9, MEF2A, MEF2C, MEF2D, POU2F1, RUNX1, ZNF91

miRNA regulators (miRDB)

148 targeting MYH10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• analysis of kinetic mechanism of non-muscle myosin IIB (PMID:12704189)
• anillin has a role in spatially regulating the contractile activity of myosin II during cytokinesis (PMID:15496454)
• In leukocytes, the activity of non-muscle myosin II is essential for cell migration, and it is not essential for tumor cell migration. (PMID:15619008)
• Assessment of solubility of a series of truncated recombinant rod fragments of nonmuscle myosin IIB at various concentrations of NaCl. (PMID:15628858)
• mutations and alternative splicing alter the enzymatic and motile activity of nonmuscle myosins II-B and II-C (PMID:15845534)
• SMemb/NMMHC-B is expressed in proliferating smooth muscle cells and correlates with phenotypic changes from a contractive to a proliferative type. The stromal cells of the prostate play a role in the regulation of prostatic growth and function. (PMID:16257837)
• These results indicate that PKCgamma regulates NMHC-IIB phosphorylation and cellular localization in response to EGF stimulation. (PMID:16394101)
• Myosin II-B resides in a complex with p21-activated kinase 1 (PAK1) and atypical protein kinase C (PKC) zeta (aPKCzeta) and the interaction between these proteins is EGF-dependent. (PMID:16611744)
• myosin IIA and IIB isoforms are regulated by different signaling pathways to perform distinct cellular activities (PMID:17020881)
• estrogen increases NMM-II-B MgATPase activity independent of NMM-II-B filamentation status (PMID:17023528)
• The N-terminal 57 residues (N-57) and C-terminal 63 residues (C-63) of C-terminal 305-residue rod fragment of the myosin IIB heavy chain (BRF305) are involved in self-recognition when myosin IIB molecules assemble into homo-filament. (PMID:17202408)
• downregulation of myosin II-B, the major myosin isoform in neurons, is able to increase Abeta deposition, concomitantly altering the subcellular localization of APP (PMID:17727819)
• MHC expression profile in the CXMDJ diaphragm differed from that in mdx mice. This indicates the dystrophic dog is a more appropriate model to investiagte respiratory failure in dystrophin deficiency. (PMID:18182116)
• We conclude that myosin II regulates the spherical shape of epithelial cysts by controlling actin polymerization at the cyst surface. (PMID:18460584)
• Expression of full-length human NMHC-IIA and -IIB in 10 T1/2 cells demonstrated that flectin antibody recognizes both isoforms (PMID:18697221)
• Data show that swapping a small C-terminal portion of the tail between myosin IIA and IIB inverts the distinct distribution of these isoforms in migrating cells. (PMID:18843042)
• cMyBP-C phosphorylation is necessary for basal myocardial function in the beta-MyHC background and can preserve function after ischemia/reperfusion injury (PMID:19237661)
• Myosin II tailpiece determines its paracrystal structure, filament assembly properties, and cellular localization (PMID:19553683)
• Data suggest a role for NM IIB in TNFR1 endocytosis and the formation of the death inducing signaling complex (DISC). (PMID:20564232)
• Data suggest that myosin-II and ERM proteins modulate mechanical properties in oocytes, contributing to cell polarity and to completion of meiosis. (PMID:20660156)
• Data conclude that P-cadherin counteracts the expression and function of myosin II-B, resulting in the suppression of the invasive and migratory behaviour of BLM melanoma cells. (PMID:20860798)
• Results suggest that IIA and IIB can form hetero-filaments in an isoform-independent manner, and that a factor like Mts1 can remove one isoform from the hetero-filament, resulting in a formation of homo-filaments consisting of another isoform. (PMID:21106542)
• a signaling complex containing c-Cbl and myosin IIA plays a crucial role in blebbing and macropinocytosis during viral infection in KSHV infection. (PMID:21203488)
• In the context of inflammation, myeloid cells may limit axonal repair in the central nervous system via a myosin II-dependent mechanism. (PMID:21737147)
• Increased NMM (nonmuscle myosin II) IIA, NMM IIB and AT expression in keloid fibroblasts compared with scant staining in normal surrounding dermis, is reported. (PMID:21792479)
• Data show that inhibition of non-muscle myosin II ATPase by blebbistatin completely blocks enucleation of human erythroblasts; results suggest that NMMHC-IIB is synthesized in erythroblasts and is required for erythroblast enucleation. (PMID:22049517)
• MYH10 detection is associated with inherited platelet disorders and myeloid neoplasms with abnormalities in RUNX1 and FLI1. (PMID:22677128)
• The myosin-IIB is unpolarized in cells on soft matrix in 2D and also within soft 3D collagen, with rearward polarization of MIIB emerging only as cells migrate from soft to stiff matrix. (PMID:23128239)
• The data show that although NM IIA and IIB form filaments with similar properties, NM IIC forms filaments that are less well suited to roles such as tension maintenance within the cell. (PMID:24072716)
• Supervillin concentrates activated and total myosin II at the furrow, and simultaneous knockdown of supervillin and anillin additively increases cell division failure. (PMID:24088567)
• The findings suggest that elevated NMHCIIb levels contribute to meningioma tumor formation and progression. (PMID:24858044)
• cellular quiescence induces Mec17 to couple the production of acetylated microtubules and Myh10, whose accumulation overcomes the inhibitory role of Myh9 and initiates ciliogenesis (PMID:25494100)
• Myosin isoforms impact single-fiber force generation and may lead to alterations in whole skeletal muscle performance. (PMID:25567808)
• A receptor type-protein tyrosine phosphatase alpha-Src family kinase-Rap1 pathway was identified as responsible for recruiting myosin IIB to the zonula adherens in epithelial cells and supporting contractile tension. (PMID:25631816)
• The role of nonmuscle myosin II (NMII)-B in front-back migratory cell polarity is controlled by a short stretch of amino acids containing five serines. (PMID:25869664)
• Our results indicate that MYH10 contributes to ciliogenesis in RPE1 cells by promoting cortical actin-dependent centriole migration. (PMID:25881509)
• myosin IIA and IIB heavy chains play distinct and non-redundant roles in matrix remodeling (PMID:26136073)
• Data show that myosin II supports a stable Rho zone at the at E-cadherin junctions. (PMID:26368311)
• We identify three mosaic missense and likely-gene disrupting mutations in genes previously implicated in ASD (KMT2C, NCKAP1, and MYH10) in probands but none in siblings. We find a strong ascertainment bias for mosaic mutations in probands relative to their unaffected siblings (PMID:27632392)
• Myosin IIA and IIB are essential for the formation of transverse arcs and ventral stress fibers, respectively. Furthermore, the study illustrated the roles of both isoforms in lamellar flattening and also raised the possibility that actin filaments in ventral stress fibers are in a stretched conformation. (PMID:29467250)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	myh10	ENSDARG00000000103
mus_musculus	Myh10	ENSMUSG00000020900
rattus_norvegicus	Myh10	ENSRNOG00000002886

Paralogs (44): MYH13 (ENSG00000006788), MYO16 (ENSG00000041515), MYO9A (ENSG00000066933), MYO3B (ENSG00000071909), MYH7B (ENSG00000078814), MYO15A (ENSG00000091536), MYH7 (ENSG00000092054), MYO3A (ENSG00000095777), MYO9B (ENSG00000099331), MYH9 (ENSG00000100345), MYH14 (ENSG00000105357), MYH1 (ENSG00000109061), MYH3 (ENSG00000109063), MYH2 (ENSG00000125414), MYO1B (ENSG00000128641), MYO5C (ENSG00000128833), CGNL1 (ENSG00000128849), MYH8 (ENSG00000133020), MYH11 (ENSG00000133392), MYO18B (ENSG00000133454), CCDC102A (ENSG00000135736), MYO1G (ENSG00000136286), MYO7A (ENSG00000137474), MYO1F (ENSG00000142347), CGN (ENSG00000143375), TMF1 (ENSG00000144747), MYH15 (ENSG00000144821), MYO10 (ENSG00000145555), CCDC102B (ENSG00000150636), MYO1E (ENSG00000157483), CCDC158 (ENSG00000163749), MYO1A (ENSG00000166866), MYO5B (ENSG00000167306), MYO7B (ENSG00000169994), MYO1H (ENSG00000174527), MYO1D (ENSG00000176658), MYO18A (ENSG00000196535), MYO6 (ENSG00000196586), MYO5A (ENSG00000197535), MYH6 (ENSG00000197616)

Protein

Protein identifiers

Myosin-10 — P35580 (reviewed: P35580)

Alternative names: Cellular myosin heavy chain, type B, Myosin heavy chain 10, Myosin heavy chain, non-muscle IIb, Non-muscle myosin heavy chain B, Non-muscle myosin heavy chain IIb

All UniProt accessions (4): A0A8I5KSC2, A0A8I5KTT7, A0A8I5KZ38, P35580

UniProt curated annotations — full annotation on UniProt →

Function. Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2. During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the central part but not the margins of spreading cells), and lamellipodial extension; this function is mechanically antagonized by MYH9. (Microbial infection) Acts as a receptor for herpes simplex virus 1/HHV-1 envelope glycoprotein B.

Subunit / interactions. Myosin is a hexameric protein that consists of 2 heavy chain subunits (MHC), 2 alkali light chain subunits (MLC) and 2 regulatory light chain subunits (MLC-2). Interacts with PLEKHG6. Interacts with ECPAS. Interacts with KIF26B. Interacts with LARP6. Interacts with MCC. Interacts with CFAP95. (Microbial infection) Interacts with herpes simplex virus 1/HHV-1 envelope glycoprotein B.

Subcellular location. Cell projection. Lamellipodium Cell membrane.

Tissue specificity. Isoform 1 is expressed in cerebellum and spinal chord. Isoform 2 is expressed in cerebrum and retina. Isoform 3 is expressed in the cerebrum and to a much lower extent in cerebellum.

Post-translational modifications. Phosphorylated by ABL2.

Disease relevance. Associated with severe intellectual disability, microcephaly, and feeding difficulties as well as cerebral atrophy.

Domain organisation. The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.

Similarity. Belongs to the TRAFAC class myosin-kinesin ATPase superfamily. Myosin family.

Isoforms (5)

UniProt ID	Names	Canonical?
P35580-1	1	yes
P35580-2	2
P35580-3	3
P35580-4	4
P35580-5	5

RefSeq proteins (4): NP_001242941, NP_001243024, NP_001362195, NP_005955 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000048	IQ_motif_EF-hand-BS	Binding_site
IPR001609	Myosin_head_motor_dom-like	Domain
IPR002928	Myosin_tail	Domain
IPR004009	SH3_Myosin	Domain
IPR008989	Myosin_S1_N	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR036961	Kinesin_motor_dom_sf	Homologous_superfamily

Pfam: PF00063, PF00612, PF01576, PF02736

UniProt features (95 total): helix 33, modified residue 18, strand 18, splice variant 4, sequence conflict 4, region of interest 4, domain 3, compositionally biased region 3, turn 3, sequence variant 2, chain 1, binding site 1, coiled-coil region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4PD3	X-RAY DIFFRACTION	2.84

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P35580-F1	76.44	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 178–185

Post-translational modifications (18): 18, 442, 1145, 1241, 1301, 1645, 1930, 1935, 1937, 1938, 1939, 1940, 1952, 1956, 1960, 1975, 214, 214

Function

Pathways and Gene Ontology

Reactome pathways

16 pathways

ID	Pathway
R-HSA-3928663	EPHA-mediated growth cone collapse
R-HSA-416572	Sema4D induced cell migration and growth-cone collapse
R-HSA-5625740	RHO GTPases activate PKNs
R-HSA-5625900	RHO GTPases activate CIT
R-HSA-5627117	RHO GTPases Activate ROCKs
R-HSA-5627123	RHO GTPases activate PAKs
R-HSA-1266738	Developmental Biology
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-373755	Semaphorin interactions
R-HSA-400685	Sema4D in semaphorin signaling
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 438 (showing top): GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_MITOTIC_CYTOKINESIS, WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, E2F_Q4, GOBP_HINDBRAIN_DEVELOPMENT, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_METENCEPHALON_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_CARDIAC_SEPTUM_DEVELOPMENT, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_CORONARY_VASCULATURE_DEVELOPMENT, E2F4DP1_01, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, KAAB_FAILED_HEART_ATRIUM_DN, GCANCTGNY_MYOD_Q6

GO Biological Process (34): mitotic cytokinesis (GO:0000281), in utero embryonic development (GO:0001701), neuron migration (GO:0001764), plasma membrane repair (GO:0001778), cardiac septum development (GO:0003279), exocytosis (GO:0006887), substrate-dependent cell migration, cell extension (GO:0006930), nuclear migration (GO:0007097), cell adhesion (GO:0007155), axon guidance (GO:0007411), adult heart development (GO:0007512), regulation of cell shape (GO:0008360), fourth ventricle development (GO:0021592), lateral ventricle development (GO:0021670), third ventricle development (GO:0021678), cerebellar Purkinje cell layer development (GO:0021680), actin filament-based movement (GO:0030048), actomyosin structure organization (GO:0031032), aorta development (GO:0035904), symbiont entry into host cell (GO:0046718), positive regulation of protein secretion (GO:0050714), neuromuscular process controlling balance (GO:0050885), cardiac myofibril assembly (GO:0055003), ventricular cardiac muscle cell development (GO:0055015), cardiac muscle cell proliferation (GO:0060038), retina development in camera-type eye (GO:0060041), coronary vasculature development (GO:0060976), postsynaptic actin cytoskeleton organization (GO:0098974), axonogenesis (GO:0007409), brain development (GO:0007420), heart development (GO:0007507), actin cytoskeleton organization (GO:0030036), myofibril assembly (GO:0030239), neuron projection development (GO:0031175)

GO Molecular Function (12): microfilament motor activity (GO:0000146), virus receptor activity (GO:0001618), actin binding (GO:0003779), calmodulin binding (GO:0005516), ATP binding (GO:0005524), RNA stem-loop binding (GO:0035613), ADP binding (GO:0043531), mRNA 5’-UTR binding (GO:0048027), actin filament binding (GO:0051015), nucleotide binding (GO:0000166), cytoskeletal motor activity (GO:0003774), protein binding (GO:0005515)

GO Cellular Component (31): stress fiber (GO:0001725), nucleus (GO:0005634), cytoplasm (GO:0005737), spindle (GO:0005819), cytosol (GO:0005829), brush border (GO:0005903), cell cortex (GO:0005938), cytoplasmic side of plasma membrane (GO:0009898), cell surface (GO:0009986), myosin complex (GO:0016459), myosin II complex (GO:0016460), sarcoplasm (GO:0016528), lamellipodium (GO:0030027), growth cone (GO:0030426), midbody (GO:0030496), neuromuscular junction (GO:0031594), cleavage furrow (GO:0032154), myosin filament (GO:0032982), actomyosin (GO:0042641), neuronal cell body (GO:0043025), dendritic spine (GO:0043197), extracellular exosome (GO:0070062), myosin II filament (GO:0097513), postsynaptic actin cytoskeleton (GO:0098871), glutamatergic synapse (GO:0098978), plasma membrane (GO:0005886), membrane (GO:0016020), axon (GO:0030424), cell projection (GO:0042995), neuron projection (GO:0043005), supramolecular fiber (GO:0099512)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
RHO GTPase Effectors	4
Axon guidance	2
EPH-Ephrin signaling	1
Sema4D in semaphorin signaling	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Semaphorin interactions	1
Nervous system development	1
Developmental Biology	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
anatomical structure development	5
cellular anatomical structure	5
ventricular system development	3
cytoplasm	3
adenyl ribonucleotide binding	2
actin cytoskeleton	2
myosin complex	2
mitotic cell cycle	1
cytoskeleton-dependent cytokinesis	1
mitotic cell cycle process	1
chordate embryonic development	1
cell migration	1
generation of neurons	1
plasma membrane organization	1
wound healing	1
cardiac chamber development	1
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
substrate-dependent cell migration	1
plasma membrane bounded cell projection assembly	1
intracellular transport	1
nucleus localization	1
establishment of organelle localization	1
cellular process	1
axonogenesis	1
neuron projection guidance	1
heart development	1
regulation of cell morphogenesis	1
regulation of biological quality	1
hindbrain development	1
telencephalon development	1
cerebellar cortex development	1
actin filament-based process	1
actin cytoskeleton organization	1
artery development	1
viral life cycle	1
symbiont entry into host	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1

Protein interactions and networks

STRING

2656 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYH10	SHROOM3	Q8TF72	722
MYH10	MYL9	P24844	720
MYH10	KLF5	Q13887	696
MYH10	MYL6	P16475	695
MYH10	TPM4	P07226	646
MYH10	KIF26B	Q2KJY2	604
MYH10	FLNB	O75369	593
MYH10	MYH9	P35579	592
MYH10	CPT1C	Q8TCG5	589
MYH10	CPT1B	Q92523	589
MYH10	NECTIN3	Q9NQS3	589
MYH10	TPM1	P09493	583
MYH10	MYLK	Q15746	575
MYH10	CALML3	P27482	570
MYH10	TPM2	P06468	569

IntAct

206 interactions, top by confidence:

A	B	Type	Score
NS	PIK3R2	psi-mi:“MI:0914”(association)	0.750
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
MYL6	MYH9	psi-mi:“MI:0914”(association)	0.640
SOX2	MYH10	psi-mi:“MI:0914”(association)	0.530
MYL6	MYL6B	psi-mi:“MI:0914”(association)	0.530
S100A4	OIP5	psi-mi:“MI:0914”(association)	0.530
VCAM1	PSMD11	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
MYH10	MYH10	psi-mi:“MI:0407”(direct interaction)	0.440
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
Kif26b	MYH10	psi-mi:“MI:0915”(physical association)	0.400
MYH10	HSPA5	psi-mi:“MI:0915”(physical association)	0.400
IL1R1	MYH10	psi-mi:“MI:0915”(physical association)	0.400
EFHD2	MYH10	psi-mi:“MI:0915”(physical association)	0.400
ATP6V1B1	MYH10	psi-mi:“MI:0915”(physical association)	0.400
PSMD8	MYH10	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (506): MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-Western), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Reconstituted Complex), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS), MYH10 (Affinity Capture-MS)

ESM2 similar proteins: A0MP03, A4RE77, A8N2Y6, B0CRJ3, E1BPK6, O08638, P02563, P02564, P10587, P11055, P12847, P12883, P13538, P13540, P13541, P13542, P14105, P35579, P35580, P35748, P35749, P49824, P79293, Q01989, Q02566, Q076A6, Q076A7, Q1DLP2, Q258K2, Q27991, Q29122, Q5ZLA6, Q61879, Q62812, Q63862, Q64331, Q8MJU9, Q8MJV1, Q8VDD5, Q91Z83

Diamond homologs: A2AQP0, A7E2Y1, F1PT61, F4I507, F4I5Q6, F4IVR7, G3UW82, K7U9N8, O08638, O14157, O94477, P02563, P02564, P02565, P02566, P02567, P04461, P05659, P05661, P08799, P08964, P10587, P11055, P12844, P12845, P12847, P12882, P12883, P13533, P13535, P13538, P13539, P13540, P13541, P13542, P14105, P19524, P21271, P24733, P32492

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
PRKCZ	down-regulates	MYH10	phosphorylation
MEF2A	“up-regulates quantity by expression”	MYH10	“transcriptional regulation”
MEF2D	“up-regulates quantity by expression”	MYH10	“transcriptional regulation”
MEF2C	“up-regulates quantity by expression”	MYH10	“transcriptional regulation”
POU2F1	“up-regulates quantity by expression”	MYH10	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 214 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RIP-mediated NFkB activation via ZBP1	5	21.9×	1e-04
Signaling by ERBB2 ECD mutants	5	21.9×	1e-04
RHO GTPases activate PAKs	6	21.3×	2e-05
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	6	20.4×	2e-05
Tie2 Signaling	5	19.6×	1e-04
FCERI mediated MAPK activation	7	15.8×	2e-05
Downstream signal transduction	6	14.9×	1e-04
TRAF6 mediated NF-kB activation	5	14.9×	4e-04

GO biological processes:

GO term	Partners	Fold	FDR
centriole replication	6	23.4×	1e-04
response to muscle stretch	5	20.4×	1e-03
canonical NF-kappaB signal transduction	7	13.6×	3e-04
tumor necrosis factor-mediated signaling pathway	6	10.6×	6e-03
intrinsic apoptotic signaling pathway in response to DNA damage	6	10.3×	6e-03
positive regulation of miRNA transcription	6	9.3×	9e-03
positive regulation of canonical NF-kappaB signal transduction	14	5.4×	2e-04
negative regulation of neuron apoptotic process	9	5.3×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

334 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	7
Uncertain significance	254
Likely benign	23
Benign	14

Top pathogenic / likely-pathogenic (11)

Variant ID	HGVS	Classification
208680	NM_001256012.3(MYH10):c.2815G>T (p.Glu939Ter)	Pathogenic
2578521	NM_001256012.3(MYH10):c.4054C>T (p.Gln1352Ter)	Pathogenic
3235270	NM_001256012.3(MYH10):c.3352AAG[1] (p.Lys1119del)	Pathogenic
625873	NM_001256012.3(MYH10):c.4505G>C (p.Arg1502Pro)	Pathogenic
1703439	NM_001256012.3(MYH10):c.2036G>A (p.Gly679Asp)	Likely pathogenic
3253330	NM_001256012.3(MYH10):c.1183C>A (p.Leu395Ile)	Likely pathogenic
3372889	NM_001256012.3(MYH10):c.3013del (p.Lys1004_Val1005insTer)	Likely pathogenic
3764196	NM_001256012.3(MYH10):c.2123G>A (p.Arg708His)	Likely pathogenic
3769338	NM_001256012.3(MYH10):c.5175+2T>C	Likely pathogenic
3915390	NM_001256012.3(MYH10):c.1511T>C (p.Leu504Pro)	Likely pathogenic
4527601	NM_001256012.3(MYH10):c.1480C>T (p.Gln494Ter)	Likely pathogenic

SpliceAI

6172 predictions. Top by Δscore:

Variant	Effect	Δscore
17:8476872:TCA:T	donor_loss	1.0000
17:8476873:CA:C	donor_loss	1.0000
17:8476874:A:AC	donor_gain	1.0000
17:8476875:C:CC	donor_gain	1.0000
17:8476875:C:CG	donor_loss	1.0000
17:8477046:CAT:C	acceptor_gain	1.0000
17:8477046:CATC:C	acceptor_loss	1.0000
17:8477046:CATCT:C	acceptor_gain	1.0000
17:8477048:TCT:T	acceptor_loss	1.0000
17:8477049:C:CC	acceptor_gain	1.0000
17:8477050:T:C	acceptor_gain	1.0000
17:8477050:T:TC	acceptor_gain	1.0000
17:8477059:G:C	acceptor_gain	1.0000
17:8477059:G:GC	acceptor_gain	1.0000
17:8477062:CA:C	acceptor_gain	1.0000
17:8477063:A:AC	acceptor_gain	1.0000
17:8477063:A:C	acceptor_gain	1.0000
17:8477063:A:T	acceptor_gain	1.0000
17:8477069:C:CT	acceptor_gain	1.0000
17:8477070:A:T	acceptor_gain	1.0000
17:8478327:T:TA	donor_gain	1.0000
17:8478447:C:CC	acceptor_gain	1.0000
17:8480104:TCTTA:T	donor_loss	1.0000
17:8480105:CTTA:C	donor_loss	1.0000
17:8480106:TTA:T	donor_loss	1.0000
17:8480107:TA:T	donor_loss	1.0000
17:8480108:A:AC	donor_gain	1.0000
17:8480108:AC:A	donor_loss	1.0000
17:8480109:C:CC	donor_gain	1.0000
17:8480109:CTTGG:C	donor_gain	1.0000

AlphaMissense

13287 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:8476942:A:G	L1907P	1.000
17:8476948:C:G	R1905P	1.000
17:8476960:C:G	R1901P	1.000
17:8476961:G:T	R1901S	1.000
17:8490443:A:G	L1563P	1.000
17:8490467:A:G	L1555P	1.000
17:8504697:A:G	L1168P	1.000
17:8504736:A:G	L1155P	1.000
17:8504748:A:G	L1151P	1.000
17:8504752:C:G	A1150P	1.000
17:8504757:A:G	L1148P	1.000
17:8512594:C:G	A906P	1.000
17:8512618:C:G	A898P	1.000
17:8512623:A:G	L896P	1.000
17:8512635:A:G	L892P	1.000
17:8513656:A:G	L845P	1.000
17:8513659:A:G	L844P	1.000
17:8513801:C:A	W835C	1.000
17:8513801:C:G	W835C	1.000
17:8513803:A:G	W835R	1.000
17:8513803:A:T	W835R	1.000
17:8513804:C:A	W834C	1.000
17:8513804:C:G	W834C	1.000
17:8513806:A:G	W834R	1.000
17:8513806:A:T	W834R	1.000
17:8513810:C:A	W832C	1.000
17:8513810:C:G	W832C	1.000
17:8513812:A:G	W832R	1.000
17:8513812:A:T	W832R	1.000
17:8513840:G:C	N822K	1.000

dbSNP variants (sampled 300 via entrez): RS1000006252 (17:8539114 A>G), RS1000008533 (17:8522125 T>C), RS1000069010 (17:8568135 C>T), RS1000097913 (17:8607017 G>C), RS1000100416 (17:8611763 C>G,T), RS1000114486 (17:8497910 T>C), RS1000184731 (17:8578494 C>T), RS1000196690 (17:8532226 G>A), RS1000219747 (17:8625272 T>A), RS1000220203 (17:8593675 T>C), RS1000223857 (17:8489799 C>T), RS1000261116 (17:8491372 T>G), RS1000270330 (17:8498247 T>C), RS1000299031 (17:8617834 T>G), RS1000310135 (17:8541824 G>A,C)

Disease associations

OMIM: gene MIM:160776 | disease phenotypes: MIM:135700, MIM:154600

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder with or without congenital anomalies	Definitive	Autosomal dominant
MYH10-related neurodevelopmental disorder with congenital anomalies	Moderate	Autosomal dominant
coloboma	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
complex neurodevelopmental disorder with or without congenital anomalies	Definitive	AD

Mondo (7): autism spectrum disorder (MONDO:0005258), congenital fibrosis of extraocular muscles (MONDO:0007614), jaw-winking syndrome (MONDO:0007946), MYH10-related neurodevelopmental disorder with congenital anomalies (MONDO:0700281), complex neurodevelopmental disorder with or without congenital anomalies (MONDO:0100465), coloboma (MONDO:0001476), congenital ptosis (MONDO:0008340)

Orphanet (5): Congenital fibrosis of extraocular muscles (Orphanet:45358), Marcus-Gunn syndrome (Orphanet:91412), OBSOLETE: Ocular coloboma (Orphanet:194), NON RARE IN EUROPE: Autism (Orphanet:106), Congenital ptosis (Orphanet:91411)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0007970	Congenital ptosis

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006484_16	Type 2 diabetes	6.000000e-07

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D003103	Coloboma	C11.250.110; C11.270.147; C16.131.384.282
C535908	Marcus Gunn phenomenon (supp.)
C566737	Ptosis, Hereditary Congenital 1 (supp.)
C580012	congenital fibrosis of the extraocular muscles (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105746 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 5,194 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL576982	QUIZARTINIB	4	4,432
CHEMBL475251	R-406	2	762

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 4 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.64	Kd	229	nM	R-406
6.12	Kd	758	nM	QUIZARTINIB
5.34	IC50	4600	nM	CHEMBL1328324

PubChem BioAssay actives

3 with measured affinity, of 168 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	1425079: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2290	uM
Quizartinib	1425079: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.7580	uM
3a-hydroxy-6-methyl-1-phenyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-one	1360375: Inhibition of human non-muscle myosin 2b	ic50	4.6000	uM

CTD chemical–gene interactions

80 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, affects methylation, decreases expression	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
Arsenic	affects cotreatment, decreases expression, increases abundance, affects methylation, increases response to substance	3
Cisplatin	decreases expression, decreases response to substance, increases expression	3
bisphenol A	affects expression, increases expression	2
Arsenic Trioxide	decreases expression, increases expression	2
Fulvestrant	affects cotreatment, increases methylation, decreases reaction, increases expression, increases phosphorylation	2
Estradiol	affects localization, increases expression, increases phosphorylation, affects binding, decreases reaction (+2 more)	2
Nickel	decreases expression	2
Valproic Acid	affects expression, decreases methylation	2
Cyclosporine	decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression, affects localization, increases expression	1
arsenite	affects binding, decreases reaction	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
cobaltous chloride	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
sulindac sulfide	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
coumarin	decreases phosphorylation	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3991792	Binding	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by ma	The target landscape of clinical kinase drugs. — Science

Cellosaurus cell lines

2 cell lines: 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5F9	MRIi003-A-1	Induced pluripotent stem cell	Male
CVCL_B5FA	MRIi003-A-2	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

304 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder